Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 8/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 10/20 | 0.42 |
| ▸ | KDM5A | P29375 | 8/20 | 0.42 |
| ▸ | KDM5C | P41229 | 1/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.41 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.41 |
| ▸ | KDM4A | O75164 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11905234 | 0.88 | MEN1 (0.63) | MEN1KMT2ALTA4HKDM5ATSHR | |
| SCHEMBL11905551 | 0.84 | MEN1 (0.44) | MEN1KMT2ALTA4HKDM4CKDM5A | |
| SCHEMBL11905077 | 0.84 | MEN1 (0.48) | MEN1KMT2ALTA4HKDM4CKDM5A | |
| SCHEMBL2490354 | 0.84 | LTA4H (0.39) | MEN1KMT2ALTA4HTSHR | |
| SCHEMBL11905289 | 0.83 | KDM4C (0.47) | MEN1KMT2ALTA4HKDM4CKDM5A | |
| SCHEMBL495591 | 0.82 | LMNA (0.38) | MEN1KMT2A | |
| SCHEMBL14438135 | 0.81 | MEN1 (0.46) | MEN1KMT2ALTA4HKDM4CKDM5A | |
| SCHEMBL21924967 | 0.80 | LMNA (0.36) | — | |
| SCHEMBL11905256 | 0.80 | MEN1 (0.44) | MEN1KMT2ALTA4HKDM5A | |
| SCHEMBL11905723 | 0.79 | KDM5A (0.45) | MEN1KMT2AKDM4CKDM5APHF8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379118-B1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | GEN ELECTRIC (US) | 2017-10-18 | — | — | EP | claimed |
| US-20140147387-A1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | GENERAL ELECTRIC COMPANY (US) | 2014-05-29 | — | — | US | claimed |
| US-8728529-B2 | Nanoparticle contrast agents for diagnostic imaging | GENERAL ELECTRIC COMPANY (US) | 2014-05-20 | — | — | US | claimed |
| US-8574549-B2 | Nanoparticle contrast agents for diagnostic imaging | GENERAL ELECTRIC COMPANY (US) | 2013-11-05 | — | — | US | claimed |
| US-20100166665-A1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | GENERAL ELECTRIC COMPANY (US) | 2010-07-01 | — | — | US | claimed |
| US-20100166664-A1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | GENERAL ELECTRIC COMPANY (US) | 2010-07-01 | — | — | US | claimed |
| EP-2379118-B1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | GEN ELECTRIC (US) | 2017-10-18 | — | — | EP | disclosed |
| EP-2379118-B1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | GEN ELECTRIC (US) | 2017-10-18 | — | — | EP | disclosed |
| US-9585974-B2 | Nanoparticle contrast agents for diagnostic imaging | GENERAL ELECTRIC COMPANY (US) | 2017-03-07 | — | — | US | disclosed |
| US-9567354-B2 | Amino acid-modified silane compounds and making method | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2017-02-14 | — | — | US | disclosed |
| US-20160296641-A1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | GE HEALTHCARE LIMITED (GB) | 2016-10-13 | — | — | US | disclosed |
| US-20160296641-A1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | GE HEALTHCARE LIMITED (GB) | 2016-10-13 | — | — | US | disclosed |
| US-9399075-B2 | Nanoparticle contrast agents for diagnostic imaging | GENERAL ELECTRIC COMPANY (US) | 2016-07-26 | — | — | US | disclosed |
| CN-102702246-A | Amino acid-modified silane compounds and making method | SHINETSU CHEMICAL CO | 2012-10-03 | — | — | CN | disclosed |
| US-20120209020-A1 | AMINO ACID-MODIFIED SILANE COMPOUNDS AND MAKING METHOD | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-08-16 | — | — | US | disclosed |
| EP-2379118-A2 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | General Electric Company (US) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010076237-A2 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | GENERAL ELECTRIC COMPANY (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100166666-A1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | GENERAL ELECTRIC COMPANY (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100166665-A1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | GENERAL ELECTRIC COMPANY (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100166664-A1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | GENERAL ELECTRIC COMPANY (US) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160296641-A1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | CD47, CD63, MACO1 | MEN1 150/4885KMT2A 1597/4885LTA4H 3062/4885 |
| US-20140147387-A1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | CD47, CD63, MACO1 | MEN1 150/4885KMT2A 1597/4885LTA4H 3062/4885 |
| US-20120209020-A1 | AMINO ACID-MODIFIED SILANE COMPOUNDS AND MAKING METHOD | BCAT2, BCAT1, ASNS | MEN1 1377/4885KMT2A 442/4885LTA4H 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.